NH TherAguix Announces Publication of Groundbreaking Study on AGuIX® Nanoparticles Enhancing Cervical Cancer Treatment
03 Julio 2024 - 7:30AM
PRESS RELEASE
NH TherAguix Announces Publication of
Groundbreaking Study on AGuIX® Nanoparticles Enhancing Cervical
Cancer Treatment
- Key
clinical milestone showcasing the potential of AGuIX®, a
next-generation nanodrug developed by NH TherAguix to improve tumor
targeting and augment efficacy when combined with
chemoradiation and brachytherapy.
- Phase I
clinical trial results demonstrate safety, tolerance, and promising
therapeutic outcomes in locally advanced cervical cancer
patients.
Paris, France, Wednesday July
3rd, 2024 – NH TherAguix (NHT), a phase
II clinical-stage biotechnology company specializing in the
development of novel nanomedicine solutions for precision
radiotherapy in oncology, today announced the publication of a
pioneering study in American Chemical Society (ACS) Nano, a high
impact factor journal. The study, titled "Theragnostic
gadolinium-based nanoparticles safely augment X-ray radiation
effects in patients with cervical cancer", provides
compelling evidence supporting the use of AGuIX® nanoparticles to
selectively enhance the effectiveness of radiotherapy in cervical
cancer treatment.
AGuIX®: A nanodrug capable of improving
the precision and effectiveness of radiotherapy
The culmination of over a decade of research,
AGuIX® nanoparticles are designed to meet the critical medical need
for more effective cancer treatments, including advanced cervical
cancer. These gadolinium-based nanoparticles enhance MRI contrast,
allowing for precise tumor visualization, and significantly amplify
the radiation dose delivered to tumor tissues, thereby improving
the efficacy of radiotherapy.
Study Highlights:
-
Safety and Tolerance: The Phase I clinical trial
involving 12 patients with locally advanced cervical cancer
demonstrated that AGuIX® nanoparticles have an excellent safety
profile, with no dose-limiting toxicities and no severe side
effects observed, especially when combined with brachytherapy or
cisplatinum-based chemoradiation.
-
Enhanced Imaging and Treatment: Based on AGuIX®
quantification through MRI, treating physicians can determine the
optimal radiotherapy dose for each patient.
-
Efficacy: All patients (n=12) achieved complete
remission of the primary tumor, with only one instance of distant
tumor recurrence, i.e. 8% compared to 30-40% recurrence according
to historical studies. The study confirms the relationship between
tumor accumulation, quantification, and encouraging tumor response
signals: an estimated dose enhancement factor of about 15% at 2 Gy
per tumor has been observed, a meaningful increase that generates a
biological response sufficient to achieve tumor control and
improved outcomes for patients.
-
Rapid Clearance: The nanoparticles are rapidly
cleared from the body, minimizing potential side effects and
allowing for efficient imaging and treatment cycles.
Dr. Olivier de Beaumont, CMO of NH
TherAguix, emphasized the significance of these findings:
"This study marks a significant advancement in the use of AGuIX® as
a novel option for cancer treatment. The ability to quantify AGuIX®
concentration in correspondence with tumor response signals with
high precision opens new avenues for personalized medicine in
oncology using companion MRI-based information."
Vincent Carrère, CEO of NH TherAguix,
commented: "We are thrilled to announce this important
publication in ACS Nano. I would like to thank the teams at IGR,
especially Professors C. Chargari and E. Deutsch, for this
remarkable clinical and translational work. It highlights the
transformative potential of AGuIX® in enhancing radiotherapy for
cervical cancer patients. These promising results reinforce our
commitment to advancing innovative cancer treatments and improving
patient outcomes."
About NH TherAguix:
www.nhtheraguix.com
NH TherAguix is a late-stage biotech company
developing AGuIX® to treat tumors and metastases in patients
undergoing radiotherapy. It is estimated that approximately 60% of
cancer patients receive radiotherapy. AGuIX® is currently being
assessed in multiple Phase II randomized trials across various
cancer types, including brain metastases, glioblastoma, and
pancreatic and lung cancers.
To date, over 190 patients have been treated
with AGuIX®. This innovation is protected by 18 patent families and
has been extensively tested in various preclinical models, with
results published in more than 80 high-impact publications.
NH TherAguix was established in 2015 following
10 years of academic research that led to the invention of AGuIX®
and the discovery of its radiosensitizing effect. The company has
raised approximately €40m of funds, including a €13m Series A in
2019 led by Bpifrance with Arbevel, Omnes, and Supernova.
Media contacts:NH TherAguixNewCap - Arthur
Rouilléarouille@newcap.fr+33 (0)1 44 71 00 15